AU2015295441B2 - Human-derived anti-huntingtin (HTT) antibodies and uses thereof - Google Patents

Human-derived anti-huntingtin (HTT) antibodies and uses thereof Download PDF

Info

Publication number
AU2015295441B2
AU2015295441B2 AU2015295441A AU2015295441A AU2015295441B2 AU 2015295441 B2 AU2015295441 B2 AU 2015295441B2 AU 2015295441 A AU2015295441 A AU 2015295441A AU 2015295441 A AU2015295441 A AU 2015295441A AU 2015295441 B2 AU2015295441 B2 AU 2015295441B2
Authority
AU
Australia
Prior art keywords
antibody
htt
antibodies
binding
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015295441A
Other languages
English (en)
Other versions
AU2015295441A1 (en
Inventor
Jan Grimm
Marcel Maier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurimmune Holding AG
Original Assignee
Neurimmune Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Holding AG filed Critical Neurimmune Holding AG
Publication of AU2015295441A1 publication Critical patent/AU2015295441A1/en
Application granted granted Critical
Publication of AU2015295441B2 publication Critical patent/AU2015295441B2/en
Priority to AU2020217427A priority Critical patent/AU2020217427B2/en
Priority to AU2024200315A priority patent/AU2024200315A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
AU2015295441A 2014-07-29 2015-07-29 Human-derived anti-huntingtin (HTT) antibodies and uses thereof Active AU2015295441B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020217427A AU2020217427B2 (en) 2014-07-29 2020-08-13 Human-derived anti-huntingtin (HTT) antibodies and uses thereof
AU2024200315A AU2024200315A1 (en) 2014-07-29 2024-01-17 Human-derived anti-Huntingtin (HTT) antibodies and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179004.8 2014-07-29
EP14179004 2014-07-29
PCT/EP2015/067327 WO2016016278A2 (en) 2014-07-29 2015-07-29 Human-derived anti-huntingtin (htt) antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020217427A Division AU2020217427B2 (en) 2014-07-29 2020-08-13 Human-derived anti-huntingtin (HTT) antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2015295441A1 AU2015295441A1 (en) 2017-02-02
AU2015295441B2 true AU2015295441B2 (en) 2020-05-14

Family

ID=51225442

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015295441A Active AU2015295441B2 (en) 2014-07-29 2015-07-29 Human-derived anti-huntingtin (HTT) antibodies and uses thereof
AU2020217427A Active AU2020217427B2 (en) 2014-07-29 2020-08-13 Human-derived anti-huntingtin (HTT) antibodies and uses thereof
AU2024200315A Pending AU2024200315A1 (en) 2014-07-29 2024-01-17 Human-derived anti-Huntingtin (HTT) antibodies and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020217427A Active AU2020217427B2 (en) 2014-07-29 2020-08-13 Human-derived anti-huntingtin (HTT) antibodies and uses thereof
AU2024200315A Pending AU2024200315A1 (en) 2014-07-29 2024-01-17 Human-derived anti-Huntingtin (HTT) antibodies and uses thereof

Country Status (11)

Country Link
US (3) US10556946B2 (OSRAM)
EP (2) EP4406549A3 (OSRAM)
JP (3) JP2017522886A (OSRAM)
KR (1) KR102643395B1 (OSRAM)
CN (2) CN107074937B (OSRAM)
AU (3) AU2015295441B2 (OSRAM)
CA (1) CA2954738A1 (OSRAM)
EA (1) EA201790165A1 (OSRAM)
IL (2) IL250180A0 (OSRAM)
MX (3) MX391037B (OSRAM)
WO (1) WO2016016278A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US10556946B2 (en) * 2014-07-29 2020-02-11 Neurimmunie Holding AG Human derived anti-Huntingtin (HTT) antibodies and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP4233901A3 (en) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
TW202110878A (zh) * 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
CN111909265B (zh) * 2020-08-25 2022-02-11 中国人民解放军军事科学院军事医学研究院 一种结合破伤风毒素重链c端结构域的人源抗体及应用
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
CN114334076B (zh) * 2021-12-23 2025-03-21 华中科技大学 一种药食同源中药玉竹的重金属概率风险评估方法及系统
KR20250116724A (ko) * 2022-12-07 2025-08-01 알케맙 테라퓨틱스 엘티디 항-헌팅틴 항체

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232052A1 (en) * 2002-01-28 2003-12-18 Ali Khoshnan Antibodies that bind to an epitope on the Huntington's disease protein
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
WO2008081008A1 (en) * 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0669986B1 (en) 1992-11-13 2003-04-09 Idec Pharmaceuticals Corporation Fully impaired consensus kozac sequences for mammalian expression
CA2116280A1 (en) 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
CN1175111C (zh) 1997-03-14 2004-11-10 艾德药品公司 将基因整合至哺乳动物细胞特定位点的方法及所用载体
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
DE69834193T2 (de) 1997-08-01 2007-04-19 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur bestimmung von amyloid-ähnlichen fibrillen oder proteinaggregaten
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
JP2003531570A (ja) * 1999-07-27 2003-10-28 アブジェニックス インク． 神経障害に関連したポリペプチド蓄積を阻害する方法および組成物
DE60126130T2 (de) 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
NZ545176A (en) 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
WO2002065136A2 (en) * 2001-02-15 2002-08-22 University Of Chicago Yeast screens for agents affecting protein folding
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US7589189B2 (en) * 2003-05-14 2009-09-15 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US8022268B2 (en) * 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
PT2370466E (pt) 2008-12-19 2015-09-21 Univ Zuerich Autoanticorpos humanos anti-alfa-sinucleína
EA031698B1 (ru) 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
CN103380145B (zh) 2010-12-17 2016-10-12 生物控股有限公司 人类抗-sod1抗体
EP2678026B1 (en) 2011-02-21 2016-05-18 The University of Zurich Ankyrin g for use in the treatment of neurodegenerative disorders
JP2014523745A (ja) * 2011-07-20 2014-09-18 メディミューン リミテッド 抗ｃｘｃｒ４抗体及び使用方法
PH12014500940A1 (en) 2011-10-28 2019-06-26 Biogen Int Neuroscience Gmbh Tdp-43 specific binding molecules
WO2014193632A2 (en) * 2013-05-29 2014-12-04 Vybion, Inc. Single chain intrabodies that alter huntingtin mutant degradation
EP3166966A1 (en) * 2014-07-10 2017-05-17 Affiris AG Substances and methods for the use in prevention and/or treatment in huntington's disease
AU2015286606A1 (en) * 2014-07-10 2017-01-12 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
US10556946B2 (en) 2014-07-29 2020-02-11 Neurimmunie Holding AG Human derived anti-Huntingtin (HTT) antibodies and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232052A1 (en) * 2002-01-28 2003-12-18 Ali Khoshnan Antibodies that bind to an epitope on the Huntington's disease protein
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
WO2008081008A1 (en) * 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
C. LANDLES ET AL, "Proteolysis of Mutant HTT Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease", JOURNAL OF BIOLOGICAL CHEMISTRY, (2010-03-19), vol. 285, no. 12, pages 8808 - 8823 *
COLBY D ET AL, "Development of a Human Light Chain Variable Domain (VL) Intracellular Antibody Specific for the Amino Terminus of HTT via Yeast Surface Display", JOURNAL OF MOLECULAR BIOLOGY, (2004-09-17), vol. 342, no. 3, pages 901 - 912 *
DAVID C. BUTLER ET AL, "Bifunctional Anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments", PLOS ONE, (2011-12-22), vol. 6, no. 12, page e29199 *
DEHAY BENJAMIN ET AL, "Mapping of the epitope of monoclonal antibody 2B4 to the proline-rich region of human Huntingtin, a region critical for aggregation and toxicity", BIOTECHNOLOGY JOURNAL, (2007-05), vol. 2, no. 5, pages 559 - 564 *
J. LEGLEITER ET AL, "Monoclonal Antibodies Recognize Distinct Conformational Epitopes Formed by Polyglutamine in a Mutant Huntingtin Fragment", JOURNAL OF BIOLOGICAL CHEMISTRY, (2009-08-07), vol. 284, no. 32, pages 21647 - 21658 *
JAN KO ET AL, "New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins", BRAIN RESEARCH BULLETIN, ELSEVIER SCIENCE LTD, OXFORD, GB, (2001-10-01), vol. 56, no. 3-4, pages 319 - 329 *
KHOSHNAN, ET AL, "Effects of intracellular expression of anti-HTT antibodies of various specificities on mutant HTT aggregation and toxicity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2002-01-22), vol. 99, no. 2, pages 1002 - 1007 *
LECERF J-M ET AL, "Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (2001-04-10), vol. 98, no. 8, pages 4764 - 4769 *
SOUTHWELL A L ET AL, "Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease", JOURNAL OF NEUROSCIENCE, (2009-10), vol. 29, no. 43, pages 13589 - 13602 *
SOUTHWELL AMBER L ET AL, "Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity", JOURNAL OF NEUROSCIENCE, (2008-09), vol. 28, no. 36, ISSN 0270-6474, pages 9013 - 9020 *

Also Published As

Publication number Publication date
WO2016016278A3 (en) 2016-03-24
CA2954738A1 (en) 2016-02-04
AU2015295441A1 (en) 2017-02-02
CN113651887A (zh) 2021-11-16
AU2020217427A1 (en) 2020-09-03
AU2020217427B2 (en) 2023-10-19
JP2017522886A (ja) 2017-08-17
MX391037B (es) 2025-03-21
CN107074937B (zh) 2021-07-27
EP4406549A2 (en) 2024-07-31
EP4406549A3 (en) 2025-01-08
JP2021003100A (ja) 2021-01-14
AU2024200315A1 (en) 2024-02-08
US20170166631A1 (en) 2017-06-15
IL276721A (en) 2020-09-30
JP7562168B2 (ja) 2024-10-07
US10556946B2 (en) 2020-02-11
NZ728372A (en) 2021-11-26
EA201790165A1 (ru) 2017-07-31
US11401325B2 (en) 2022-08-02
MX2022003704A (es) 2022-04-26
JP2023052519A (ja) 2023-04-11
MX2022003706A (es) 2022-04-26
WO2016016278A2 (en) 2016-02-04
US20200392217A1 (en) 2020-12-17
MX2017001285A (es) 2017-04-25
JP7235939B2 (ja) 2023-03-09
KR20170036785A (ko) 2017-04-03
EP3174898A2 (en) 2017-06-07
CN107074937A (zh) 2017-08-18
IL250180A0 (en) 2017-03-30
KR102643395B1 (ko) 2024-03-11
US20220332808A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
US20250154235A1 (en) Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
US20220332808A1 (en) Human-derived anti-huntingtin (htt) antibodies and uses thereof
US20240254256A1 (en) Human Anti-SOD1 Antibodies
US20240279361A1 (en) Human-derived anti-dipeptide repeats (dprs) antibody
NZ728372B2 (en) Human-derived anti-huntingtin (htt) antibodies and uses thereof
EA046697B1 (ru) Происходящие от человека антитела к гентингтину (htt) и их применение

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)